On May 9th, Dx&Vx held a new product launch conference in Wuhan, China.
At the meeting, Dx&Vx released two new products, Bilitin (phencycular quinolium bromide nasal spray) and Fushanlong (ceftran neopentyl tablets), and launched a digital operation system SCSS for primary medical institutions. In addition, Dx&Vx has also signed a cooperation agreement with KA customers to provide patients with more diversified, better and more convenient health solutions with multiple terminals, and write a new chapter in the growth of medicine.
"It is imperative to take advantage of the dragon and the four seas" Dx&VX Fushan Dragon & Bilitin new product launch ceremony
01
Exclusive innovative drug bilitin,
The high-potential varieties in the hospital go outside the hospital
In recent years, the prevalence of allergic rhinitis (AR, also known as "allergic rhinitis") in mainland China has increased significantly, and the national epidemiological survey shows that the prevalence of AR in domestic adults has increased from 11.1% in 2005 to 17.6% in 2011, and patients are often affected by a variety of comorbidities, resulting in serious economic and living burdens.
You Xuejun, associate professor of Tongji Medical College, Huazhong University of Science and Technology
Based on his rich clinical experience, Associate Professor You Xuejun from Tongji Medical College of Huazhong University of Science and Technology shared the value of cholinergic neuromodulators in the treatment of rhinitis. He introduced that AR allergens are diverse and easy to access, so more emphasis is placed on the combination of prevention and treatment, that is, environmental control, health education, drug treatment and immunotherapy. Pharmacotherapy is still the mainstay of treatment, but traditional pharmacotherapy has limitations, while nasal anticholinergics can effectively inhibit parasympathetic excitation, control airway inflammation and remodeling, and are suitable for patients who are deeply troubled by allergic rhinitis.
Phencycular quinolium bromide is a highly selective M-cholinergic receptor antagonist, which can quickly and effectively relieve the nasal symptoms of AR, including runny nose, nasal congestion, nasal itching and sneezing symptoms, and has been recommended by many guidelines at home and abroad. Bilitin is a nasal spray form, which has the characteristics of topical administration, easy to use, and rapid onset, which fills the gap in the AR drug market to a certain extent, and is a new choice for AR patients, and is also recognized by doctors in the hospital. According to Zhongkang CMH data, the sales of Bilitin have been rising for three years since its listing, and its sales will enter the TOP10 in the respiratory system-nasal drug (chemical drug) category in the grade hospital market in 2023.
Previously, the pattern of AR treatment drugs in the out-of-hospital retail market was relatively fixed, and there were no new products on the market for many years, and doctors and patients were limited in their drug choices. As the first non-hormonal and chemical Class 1 innovative drug developed in the field of AR therapy in mainland China, Bilitin is bound to break the existing market pattern, provide new options for AR patients, and inject new vitality into the retail market.
02
three generations of cephalosporin original research Fushan dragon,
Officially landed in the Chinese market
While expanding the field of anti-allergies, DX&Vx also continues to deepen the field of antibiotics and continuously upgrade its antibiotic products.
This time, Dx&Vx introduced Toyamalong, a third-generation cephalosporin original agent with high clinical value and safety, to bring high-quality products to patients in the field of anti-infection.
Chief physician and deputy director of administration of the Department of Urology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Doctoral supervisor Pang Ran
Pang Ran, chief physician, deputy director of administration, and doctoral supervisor of the Department of Urology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, introduced at the meeting that ceftran has a wide antibacterial spectrum, has antibacterial effects on both Gram-positive bacteria and Gram-negative bacteria, and can reach 91.7% for streptococcal bacteria, 91.1% for pneumococcus, and is stable against β-lactamase. It has a high clearance rate for Klebsiella pneumoniae, Proteus, Staphylococcus and Escherichia coli, so it has a good application prospect in urinary tract diseases, male genital infection, upper urinary tract stones and other urinary system diseases.
According to Zhongkang CMH data, in 2023, the sales scale of systemic antimicrobial drugs in out-of-hospital retail pharmacies will exceed 15.5 billion yuan, a year-on-year increase of 2.3%, and cephalosporins will account for nearly 30% of the market share, of which the third-generation cephalosporin will be the mainstay. As the original development agent of ceftrepren neoamyl ester, Fushan Dragon is a reference preparation for the consistency evaluation of domestic generic drugs, with a low incidence of adverse reactions, and since it was listed in Toyama, Japan in 1987, it has been verified by the market for decades, and this official entry into the Chinese market will bring safer and more effective treatment options to patients, and its subsequent performance in the field of anti-infection is worth looking forward to.
03
SCSS intelligent diagnosis and treatment system,
Contribute to the digital development of primary care
DX&VX is committed to the cause of big health, integrating medical resources through innovative research and development, not only providing safe and high-quality products for the market, but also being the practitioner and pioneer of smart medical care.
At present, with the advancement of national hierarchical diagnosis and treatment, primary medical institutions, as the "health gatekeeper", are increasingly important in channels, however, the old operation model of most primary medical institutions is difficult to undertake and meet the needs of more and more patients, and they are facing the problem of digital upgrading.
Focusing on the current pain points of primary medical care, Dx&Vx has launched the SCSS smart diagnosis and treatment system, which realizes the optimal allocation of medical resources and the efficient provision of medical services through information technology, bringing convenient, personalized and accurate services to clinics.
It is reported that the SCSS system can provide prescription management, inventory management, sales management and other services for primary medical institutions, and at the same time realize intelligent distribution through the function of air medicine pharmacy to reduce storage costs. In addition, a knowledge base of Korean and American experts has been grafted to provide academic support for doctors. The SCSS system empowers grassroots medical institutions through multi-dimensional diagnosis and treatment platforms, supply chain platforms, doctor gas stations, and point malls, helping them achieve refined management and efficient operation.
There is no doubt that in the era of informatization and big data, making good use of the smart medical system can greatly reduce labor costs, improve the operational efficiency of clinics, make primary medical institutions more focused on serving patients, and help the high-quality development of primary health care.
As an all-round pharmaceutical company, DX&Vx integrates R&D, production, service, sales and training, and has created a global biomedical R&D/sales network with a one-stop solution network, and has now developed into an all-round pharmaceutical company covering molecular testing and diagnostic services, in vitro diagnostic kit development, vaccines, pharmaceuticals and biological health products, aiming to meet the needs of patients around the world.
For a long time, Dx&Vx has adhered to the mission of serving patients and protecting health, and is committed to providing better health protection for Chinese patients. The launch of the two new products, Fushanlong and Bilitin, is an important milestone in the development of Dx&Vx, which will further improve its product architecture in the fields of respiratory, anti-infection and anti-allergy.
Liu Chundao, deputy general manager of Wuhan Keli Pharmaceutical Co., Ltd
Liu Chunzhi, deputy general manager of Wuhan Keli Pharmaceutical Co., Ltd., said that in the future, Dx&Vx will continue to adhere to the concept of "innovation, development and service" to provide patients with more high-quality and efficient treatment options, and also looks forward to working together with all partners to bring health and hope to more patients and jointly promote the prosperity and development of the medical industry.